bp-1-102 and Lung-Neoplasms

bp-1-102 has been researched along with Lung-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for bp-1-102 and Lung-Neoplasms

Article	Year
STAT3 inhibitor sensitized KRAS-mutant lung cancers to RAF inhibitor by activating MEK/ERK signaling pathway. Aging, 2019, 09-04, Volume: 11, Issue:17 Topics: Aminosalicylic Acids; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mice, Inbred BALB C; Mice, Nude; Proto-Oncogene Proteins p21(ras); Quinazolines; raf Kinases; STAT3 Transcription Factor; Sulfonamides	2019

Article

Year

STAT3 inhibitor sensitized KRAS-mutant lung cancers to RAF inhibitor by activating MEK/ERK signaling pathway.

Aging, 2019, 09-04, Volume: 11, Issue:17

Topics: Aminosalicylic Acids; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mice, Inbred BALB C; Mice, Nude; Proto-Oncogene Proteins p21(ras); Quinazolines; raf Kinases; STAT3 Transcription Factor; Sulfonamides

2019